: 08111742529 - 08129123920
Dengan Yosef Setyawan
Untuk melihat feature & spesifikasi masing-masing produk silahkan klik link di bawah :
Advanced Circulatory Systems, Inc. (ACSI) was originally founded in 1997 as CPRx LLC. Rooted in years of clinical experience with patients in cardiac arrest and at high risk for cardiac arrest, the founders were frustrated by the lack of effective and readily accessible resuscitation treatment options. With over 95 percent of US patients experiencing out-of-hospital cardiac arrest never surviving to hospital discharge, the founders were committed to improving those odds.
With funding from its founders and a small group of angel investors, ACSI began developing and marketing innovative therapies for use in increasing circulation in patient populations with states of low blood flow or perfusion, such as those suffering from sudden cardiac arrest, shock and other hypotensive conditions.
In 2002, the company’s name changed to ResQSystems, and in 2003 the company incorporated and assumed the current name, Advanced Circulatory Systems, Inc. (ACSI).
Advanced Circulatory Systems’ mission is to restore life and improve the quality of life for patients suffering cardiac arrest, low blood pressure and head injury by developing novel technologies to non-invasively increase circulation throughout the body, thereby improving the opportunity for survival and the quality of life of patients who experience major medical emergencies and life-altering circulatory conditions.
The circulatory system is the human body’s transport system for life. The body uses it to deliver oxygen to and remove waste from the brain, vital organs and other key areas of the body. Without proper circulation, organs can fail, neurological damage can occur and death can result. Advanced Circulatory Systems’ technology may be used in any medical situation where an increase in circulation of blood is of benefit. The technology is embodied in products that can be easily used by virtually anyone, from the layperson to the trained professional, and in any setting: the home, public venue, an ambulance or hospital. ACSI’s technology draws greater blood flow into the heart, resulting in increased cardiac output, which provides greater blood flow to the body’s vital organs.
Millions of people suffer life-altering and life-threatening consequences each year from nearly two dozen medical conditions and disease states that impair their circulation. These medical conditions and disease states range from one-time occurrences to chronic conditions. They include shock, traumatic brain injury, cardiac arrest, dehydration, kidney failure, congestive heart failure, wound healing, diabetes, stroke and orthostatic hypotension. The consequences of reduced circulation are severe and burden the health care system with billions of dollars of expenditures on an annual basis.
Advanced Circulatory Systems offers a proprietary technology platform protected by numerous issued US and international patents and pending patent applications that is non-invasive, instantaneous and increases the circulation of individuals to whom it is applied. This technology platform utilizes the body’s biophysical performance to enhance circulation without the use of pharmaceutical or other mechanical agents. ACSI’s technology is currently embodied in compact devices that selectively impede inspiration during breathing. This inspiratory impedance results in enhanced circulation, as evidenced by increased blood flow volume, cardiac output and systolic blood pressure.
Advanced Circulatory Systems has spent over ten years developing its circulatory enhancement technology and preparing for its commercialization to improve circulation in patients in cardiac arrest. The company has proven the clinical efficacy of its technology in a variety of studies. ACSI has successfully launched its products for increasing circulation. These products are the ResQPOD® Impedance Threshold Device (ITD) for patients who require assisted ventilation, for example, those in cardiac arrest, and the ResQGARD™ Impedance Threshold Device (ITD) for patients who are spontaneously breathing, for example, those receiving dialysis. ACSI’s technology has the potential to be beneficial in a plethora of clinical applications, including the treatment of cardiac arrest, intradialytic hypotension, dialysis, dehydration, diabetes, trauma and traumatic brain injury. Designing products for these applications involves utilizing the same core technology already incorporated in the ResQPOD and ResQGARD, and adapting it through design, user-interface and ease of use efforts to the specific target market. Advanced Circulatory Systems will continue to grow by introducing new products that use its core technology to benefit patients in need of improved circulation.